Abcuro is a company developing immunotherapies to treat autoimmunity and cancer. It offers a monoclonal antibody ABC008 that depletes cytotoxic T cells by targeting killer cell lectin-like receptor G1 (KLRG1). The company provides its product for autoimmune disorders and rare cancers, including inclusion body myositis (IBM), T cell large granular lymphocytic leukemia (T-LGLL), and T and NK cell lymphomas.